- Home
- VOR vs ACRV Comparison
VOR vs ACRV Comparison
Compare VOR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | ACRV |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 47.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VOR | ACRV |
|---|---|---|
| Price | $13.53 | $1.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $64.78 | $13.00 |
| AVG Volume (30 Days) | 549.7K | ★ 852.9K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.86 | ★ 13.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.05 |
| 52 Week High | $49.95 | $5.65 |
Technical Indicators
Market Signals| Indicator | VOR | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 47.09 |
| Support Level | $11.27 | $1.49 |
| Resistance Level | $14.73 | $1.86 |
| Average True Range (ATR) | 1.16 | 0.12 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 10.66 | 46.07 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.